Atamyo Seeking Approval for LGMD Gene Therapy Trial in Europe

Atamyo Seeking Approval for LGMD Gene Therapy Trial in Europe

310480

Atamyo Seeking Approval for LGMD Gene Therapy Trial in Europe

Atamyo Therapeutics is seeking approvals in Europe to launch its first trial testing ATA-100, its investigational gene therapy for a type of limb-girdle muscular dystrophy (LGMD). The company, a spin-off from Genethon, a Paris-based genetics research laboratory, has submitted an application asking three European nations for permission to begin clinical testing of ATA-100 for LGMD type 2I/R9, known as LGMD2I/R9. “This is a first step in our mission to bring to patients suffering from limb-girdle…

You must be logged in to read/download the full post.